Glaxo pulls plug on expanded use of Votrient After additional analysis of Phase 3 trial data, GlaxoSmithKline (GSK) decides to withdraw its European application for the use of Votrient (pazopanib) in advanced ovarian cancer. Although initial results showed an improvement in progression-free survival, further analysis failed to show a sufficient benefit-to-risk ratio to proceed. http://www.reuters.com/article/2014/03/31/us-glaxosmithkline-brief-idUSBREA2U0PB20140331
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.